199 related articles for article (PubMed ID: 32190913)
1. Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease.
Vats R; Liu S; Zhu J; Mukhi D; Tutuncuoglu E; Cardenes N; Singh S; Brzoska T; Kosar K; Bamne M; Jonassaint J; Adebayo Michael A; Watkins SC; Hillery C; Ma X; Nejak-Bowen K; Rojas M; Gladwin MT; Kato GJ; Ramakrishnan S; Sundd P; Monga SP; Pradhan-Sundd T
Hepatology; 2020 Dec; 72(6):2165-2181. PubMed ID: 32190913
[TBL] [Abstract][Full Text] [Related]
2. Impaired hemoglobin clearance by sinusoidal endothelium promotes vaso-occlusion and liver injury in sickle cell disease.
Kaminski TW; Katoch O; Li Z; Hanway CB; Dubey RK; Alagbe A; Brzoska T; Zhang H; Sundd P; Kato GJ; Novelli EM; Pradhan-Sundd T
Haematologica; 2024 May; 109(5):1535-1550. PubMed ID: 37941440
[TBL] [Abstract][Full Text] [Related]
3. Network pharmacology-based mechanism prediction and pharmacological validation of Xiaoyan Lidan formula on attenuating alpha-naphthylisothiocyanate induced cholestatic hepatic injury in rats.
Wang M; Liu F; Yao Y; Zhang Q; Lu Z; Zhang R; Liu C; Lin C; Zhu C
J Ethnopharmacol; 2021 Apr; 270():113816. PubMed ID: 33444723
[TBL] [Abstract][Full Text] [Related]
4. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
5. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice.
El Kasmi KC; Ghosh S; Anderson AL; Devereaux MW; Balasubramaniyan N; D'Alessandro A; Orlicky DJ; Suchy FJ; Shearn CT; Sokol RJ
Hepatology; 2022 Feb; 75(2):252-265. PubMed ID: 34387888
[TBL] [Abstract][Full Text] [Related]
7. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
[TBL] [Abstract][Full Text] [Related]
8. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
9. β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
Thompson MD; Moghe A; Cornuet P; Marino R; Tian J; Wang P; Ma X; Abrams M; Locker J; Monga SP; Nejak-Bowen K
Hepatology; 2018 Mar; 67(3):955-971. PubMed ID: 28714273
[TBL] [Abstract][Full Text] [Related]
10. Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis.
Kim KH; Choi JM; Li F; Arizpe A; Wooton-Kee CR; Anakk S; Jung SY; Finegold MJ; Moore DD
Endocrinology; 2018 Jun; 159(6):2435-2446. PubMed ID: 29718219
[TBL] [Abstract][Full Text] [Related]
11. Bile salt excretory pump: biology and pathobiology.
Suchy FJ; Ananthanarayanan M
J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S10-6. PubMed ID: 16819395
[TBL] [Abstract][Full Text] [Related]
12. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor.
Li T; Xu L; Zheng R; Wang X; Li L; Ji H; Hu Q
Phytomedicine; 2020 Mar; 68():153153. PubMed ID: 32018210
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.
Pradhan-Sundd T; Kato GJ; Novelli EM
Am J Physiol Cell Physiol; 2022 Aug; 323(2):C494-C504. PubMed ID: 35759437
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-derived IL-1β/NF-κB signaling mediates parenteral nutrition-associated cholestasis.
El Kasmi KC; Vue PM; Anderson AL; Devereaux MW; Ghosh S; Balasubramaniyan N; Fillon SA; Dahrenmoeller C; Allawzi A; Woods C; McKenna S; Wright CJ; Johnson L; D'Alessandro A; Reisz JA; Nozik-Grayck E; Suchy FJ; Sokol RJ
Nat Commun; 2018 Apr; 9(1):1393. PubMed ID: 29643332
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity.
Kong Y; Gao X; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Sun P; Meng Q
Eur J Pharmacol; 2018 Apr; 824():64-71. PubMed ID: 29427579
[TBL] [Abstract][Full Text] [Related]
16. NF-κB Regulation of LRH-1 and ABCG5/8 Potentiates Phytosterol Role in the Pathogenesis of Parenteral Nutrition-Associated Cholestasis.
Ghosh S; Devereaux MW; Anderson AL; Gehrke S; Reisz JA; D'Alessandro A; Orlicky DJ; Lovell M; El Kasmi KC; Shearn CT; Sokol RJ
Hepatology; 2021 Dec; 74(6):3284-3300. PubMed ID: 34310734
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
18. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.
Molinaro A; Marschall HU
Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955
[TBL] [Abstract][Full Text] [Related]
19. The ileum-liver Farnesoid X Receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats.
Zhang F; Xi L; Duan Y; Qin H; Wei M; Wu Y; Li B; Zhou Y; Wu X
Eur J Pharm Sci; 2018 Oct; 123():404-415. PubMed ID: 30077711
[TBL] [Abstract][Full Text] [Related]
20. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity.
Chen F; Ananthanarayanan M; Emre S; Neimark E; Bull LN; Knisely AS; Strautnieks SS; Thompson RJ; Magid MS; Gordon R; Balasubramanian N; Suchy FJ; Shneider BL
Gastroenterology; 2004 Mar; 126(3):756-64. PubMed ID: 14988830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
